How do differences in onset, symptoms, and treatment response arise between various mental illnesses despite substantial overlap of genetic risk factors? To address this question, we carried out deep RNA sequencing of human postmortem subgenual anterior cingulate cortex, a key component of limbic circuits linked to mental illness. Samples were obtained from 200 individuals diagnosed with bipolar disorder, schizophrenia, or major depression, and controls. Differential expression analysis in cases versus controls detected modest differences that were similar across disorders, although transcript-level differences were more pronounced. Case-case comparisons revealed greater expression differences between disorders, including many genes and transcripts that were expressed in opposite directions in each diagnostic group, compared to controls. Relative transcript abundances were associated with common genetic variants that accounted for disproportionate fractions of diagnosis-specific heritability. Inherited genetic risk factors shape the brain transcriptome and contribute to diagnostic differences between broad classes of mental illness. 
INTRODUCTION
Genome-wide association studies (GWAS) have revealed that major psychiatric disorders share many common alleles with small additive effects on risk 1, 2 . Similarly, gene expression studies in post-mortem brain tissue have found that expression changes in mental illnesses tend to be small and correlated across diagnoses. One large post-mortem study 3 found small changes in gene expression in schizophrenia (SCZ) versus controls that seemed to reflect the small frequency differences of common alleles associated with SCZ by GWAS 4 . A meta-analysis of microarray expression data drawn from several post-mortem studies found that many differentially-expressed (DE) genes were shared across major psychiatric disorders such as SCZ, autism, and bipolar disorder (BD) 5 . A large follow-up study that used RNA sequencing confirmed substantial overlap in DE genes in SCZ, BD, and autism spectrum disorder, versus controls, although transcript (isoform) level expression was more variable 6 .
If genetic risk factors and gene expression changes in brain are as similar across different mental illnesses as these studies seem to suggest, then how do diagnostic differences in onset, symptoms, and treatment response arise at all? One possibility is that diagnostically distinct genetic risk factors account for some of these differences. For example, genetic correlations as high as the 70% reported between SCZ and BD 1 are consistent with ~50% of risk alleles differing between disorders. It is also possible that published gene expression studies have overestimated the degree to which gene expression changes in post-mortem brain are similar across disorders. Even the largest sample sizes have been underpowered to detect subtle gene expression differences 3 , and those differences that have been detected may not be representative. Case-control study designs limit opportunities to detect true differences between case groups, and few published post-mortem gene expression studies have focused on direct, case-case comparisons between disorders. Moreover, few if any human postmortem studies have used methods that reveal most of the transcriptional complexity of the brain, where numerous gene isoforms are generated by alternative splicing and other mechanisms. How much of the apparent resemblance in gene expression reported among clinically distinct mental illnesses can be explained by these methodological limitations?
To address this question, we performed deep sequencing of the brain transcriptome followed by casecontrol and case-case comparisons of both gene and isoform expression in tissue obtained post-mortem from 200 individuals diagnosed with BD, SCZ, major depressive disorder (MDD), or no known psychiatric illness. Tissue was dissected from subgenual anterior cingulate cortex (sgACC), a key component of limbic circuits that have been implicated in major mood disorders and other mental illnesses 7, 8 . Total RNA was sequenced at an average depth of ~270 million reads per sample, generating high-quality expression data for ~21,000 genes and ~85,000 transcripts in 185 samples. We believe these data represent the most complete sampling of the human brain transcriptome published to date.
The results demonstrate that subtle differences in gene expression observed between broad diagnostic classes of mental illness actually reflect more pronounced and diagnosis-specific changes at the transcript level, and that these changes are shaped by inherited genetic risk factors.
RESULTS

Transcriptome Profile of the Subgenual anterior cingulate cortex (sgACC)
Total RNA from 200 postmortem brain samples (Controls=61, SCZ=46, BD=39, MDD=54) was captured using the Ribo-zero protocol (see Methods) followed by stranded, paired-end sequencing. The samples, along with demographic information and known covariates are presented in Supplementary Table 1 . After quality control, 185 samples were retained for analysis (see Methods). The analysis pipeline is presented in Supplementary Figure   1 .
In an effort to detect a more complete set of genes and transcripts than previous studies, RNA sequencing was performed at very high depth, generating ~50 billion reads at an average of ~270M reads/sample. Of these, 167M reads/sample mapped to ~21,000 Ensembl genes and ~85,000 Ensembl transcripts; identifying ~50% more transcripts than those used in previous studies 6, 9, 10 . The mapping summaries are presented in Supplementary Table   2 . Very highly expressed transcripts with >10,000 reads/transcript comprised 1% of the total reads, while transcripts with <100 reads comprised 56% (Supplementary Figure 2) . We detected an average of 5 isoforms/gene. The greatest number of isoforms (49 each) were detected for the genes MUC20-OT1 (a noncoding RNA) and TCF4, which has been associated with SCZ, autism, and intellectual disability [11] [12] [13] . Table 12 ). Some of the genes reported here for the first time in association with a psychiatric GWAS locus include: CORO7, an F-actin regulator thought to play an essential role in maintenance of Golgi apparatus morphology; TSHR, which codes for the thyroid stimulating hormone receptor, previously reported to harbor rare, loss-of-function mutations in ADHD 19 ; and ORMDL3, which plays a role in sphingolipid synthesis and regulation of Ca2+ levels in the endoplasmic reticulum 20 .
Integration of our eGene data with the latest BD GWAS results detected 4 pleiotropic variants, increasing to 16 when all brain samples were considered (Supplementary (Figure 2b) , and the correlation of FC values across diagnoses (linear regression R 2 ) was 0.43-0.44% (Figure 3b ). For some genes, the same transcript was DE in all 3 disorders (e.g., NR4A1-213, Figure 4 ), but there were several instances of alternative isoform usage, where distinct transcripts of the same gene were DE in different disorders (e.g., Figure 4 ). Table 22 -24) . Since the absolute difference between case groups is larger for opposing transcripts (Figure 5d -5e), when power is limited such transcripts should be more easily detected in case-case than in case-control comparisons.
HDAC11, NR4A1;
Comparisons of major mood disorders (BD and MDD) compared to SCZ found additional transcripts that were regulated in the same direction in the mood disorders and in the opposite direction in SCZ (Supplementary Table 27 ).
Validation of DE genes and transcripts
Validation of the RNAseq analyses was carried out in the same 185 samples using real time quantitative PCR (RT-qPCR) using 6 genes and transcripts with read counts over 500 (see Methods). All tested genes and transcripts showed the same direction of effect with respect to diagnosis as was detected in the RNAseq analyses.
This result was significantly different from chance (binomial p-value of 0.016). sQTLs within GWAS loci. As observed with eQTLs, some sQTLs may be pleiotropically associated with disease risk. To investigate this, we searched for SNPs that were identified as risk alleles by GWAS and as sQTLs in the present study. We used only those sQTLs that were detected in sgACC from self-reported Caucasian brain donors, since existing GWAS are mainly based on samples of European ancestry,.
Functional enrichment of DE genes and transcripts
Overall, about 10-25% of GWAS loci we investigated harbored one or more significant sQTLs. In SCZ, of 430 genome-wide significant GWAS SNPs 25 , 56 were identified as an sQTL in the present study, implicating 44 genes. Of these, 15 different genes are linked here for the first time to functional variation within a SCZ Both eQTLs and sQTLs accounted for disproportionate fractions of heritability in SCZ, BD, and MDD (Table 3) . However, sQTLs, which comprised only 1% of all SNPs, explained 16-21% of the heritability, a 14-18
fold enrichment (p<0.01). sQTLs showed even greater enrichment of heritability for some other major psychiatric disorders, but not all. sQTLs explained 29% of the heritability of autism spectrum disorders (25-fold enrichment, p<0.001) and 41% of the heritability of attention deficit hyperactivity disorder (36.6-fold enrichment, p<0.001), but showed no significant enrichment for Alzheimer Disease or anxiety disorders.
DISCUSSION
We have employed deep transcriptome sequencing in post-mortem brain tissue to address a central question in the pathophysiology of mental illness: How do diagnostic differences in onset, symptoms, and treatment response arise despite substantial overlaps of genetic risk factors across disorders? The findings show that subtle differences in gene expression observed between broad diagnostic classes of mental illness actually reflect more pronounced and diagnosis-specific changes at the transcript level. These changes often involve alternative isoform usage, are most evident in case-case comparisons, and are influenced by common genetic variants that also play a disproportionately large role in the inherited risk of mental illness.
These findings should be considered in light of several limitations. While this was one of the larger RNA sequencing studies performed to date in human brain tissue, sample size was limited, with less than 100 individuals in each diagnostic category. This limits power to detect small changes in expression. This limitation was offset by complementing the typical case-control comparisons with case-case comparisons between distinct psychiatric diagnoses. This approach should be more powerful in the face of opposing expression changes between case groups, which we detected for hundreds of genes and transcripts. As in all human post-mortem studies, diverse factors effect post-mortem expression, not all of which can be measured or controlled, increasing noise and introducing the risk for bias. We attempted to address this by stringent quality control, careful adjustment for key covariates, and confirmation of top findings by use of alternative approaches. Also inherent in human post-mortem samples is the inability to draw confident distinctions between expression changes that cause disease and those that result from disease or its treatment. The kind of integrative genomic approaches we employed, which draw causal inferences on the basis of published GWAS 17 , partially address this issue but still lack power to distinguish between correlated causal and non-causal events. This study focused on a single brain region, albeit one that has been little studied, so cannot shed light on transcriptional differences between brain regions that may be important in disease. While we employed very deep RNA-sequencing to detect rare transcripts and better identify alternative splicing, the data still contain relatively few sequencing reads that uniquely map to splice junctions, limiting the confidence with which transcript-level differences can be ascribed to differences in alternative splicing rates and mechanisms. Finally, the sequencing was performed on bulk tissue.
This means that the results lack cellular resolution, but also that they comprise a much larger portion of the brain transcriptome than can usually be achieved with current single cell technologies.
Several large postmortem brain gene expression studies of mental illness have been published recently, some with larger samples than were employed here 6, 9, 34 . The present study complements those larger studies in several ways. None of those studies evaluated the subgenual anterior cingulate cortex (sgACC), a key component of limbic circuits that has been implicated in reward, impulse control, and emotion regulation 5 , as well as in major mood disorders. 7, 8, [35] [36] [37] To date, genome-wide expression studies in ACC or sgACC have been carried out in fewer than 50 samples [38] [39] [40] . Some of the genes and transcripts whose expression we found to be associated with GWAS hits were detected only in ACC, consistent with the idea that common risk alleles may regulate expression in a tissue-specific manner 41 . None of the previous studies employed RNA-sequencing at a depth comparable to the 270 million reads per sample used here, which enabled us to capture at least 10 reads per sample in more than 21,000 genes and 85,000 transcripts. This was particularly beneficial in transcript-level analyses, which found numerous DE transcripts, shifts in relative transcript abundance that were associated with numerous common variants (sQTLs), and strong evidence that such variants play a disproportionately large role in the heritability of SCZ, BD, and MDD. The present study was also unique in its use of case-case comparisons, which revealed unexpectedly large numbers of genes and transcripts that were DE between case groups. Many DE genes and transcripts showed opposite directions of expression between cases, when compared to controls, suggesting one important way in which genetically correlated disorders can express contrasting transcriptomes that could reflect diagnostic differences in onset, symptoms, or treatment response.
Most of the transcripts whose expression was associated with common genetic variants in this study are predicted to arise from classical alternative splicing mechansims. These findings are consistent with previous results suggesting that alternative splicing plays an important role in differential transcriptome expression in major psychiatric and other disorders and that it is mediated, at least in part, by some of the same genetic variants identified by GWAS 32 . A secondary analysis of RNA-sequencing data from psychiatrically unaffected individuals drawn from the CMC dataset found evidence of alternative splicing associated with common genetic variants, some of which overlapped with known SCZ risk loci, but did not assess for differential expression in individuals diagnosed with SCZ 30 . A recent study of post-mortem human cortex at 85 million reads per sample detected shifting isoform usage across pre-and post-natal life and a number of transcripts that were DE in SCZ 41 .
Our results support those previous findings and demonstrate that common genetic variants associated with relative transcript abundance (sQTLs) account for disproportionate fractions of disorder-specific heritability.
Taken together, these findings suggest that inherited genetic risk factors shape the brain transcriptome and contribute to diagnostic differences between broad classes of mental illness. This may be one important mechanism by which diagnostically distinctive patterns of transcript expression arise despite the known correlations in inherited genetic risk factors across major psychiatric disorders. Despite the growing recognition of the importance and complexity of alternative splicing, its role in the development of neuropsychiatric diseases is still poorly understood. Much future work is needed to characterize the functions of alternative transcripts, the timing of alternative isoform usage during disease course, and the potential impact that therapeutic agents may have on the expression or function of particular isoforms in specific brain regions and cell types.
METHODS
See Methods document
Data availability
The raw data can be downloaded from dbGAP at https://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000979.v2.p2
Tissue availability Figure   10 ). Lowess modeling was performed by disease class to remove noise-biased expression, thus resulting in ~21K genes (Supplementary Figure 11 ).
Covariates:
We tested for a total of 23 known covariates: RIN, age, gender, reported race, pH, RNA extraction batch, library batch, postmortem interval (PMI), PMI confidence, GC percent, manner of death, smoking status, source location, height, and weight, along with available data on alcohol, anti-depressants, mood stabilizers, benzodiazepines, nicotine, THC, cocaine, and opiates. Univariate and step-wise AIC regression analysis was performed on all the covariates. Any covariates that were significant after the multiple testing were included in the downstream analysis.
Gene-and transcript-level analysis:
We normalized the raw counts using conditional quantile normalization 4 (CQN) (https://bioconductor.org/packages/release/bioc/html/cqn.html) which corrects for library size, gene length and GC content. These normalized counts were then imported to DESeq2 so these were included in the downstream analysis. A total of 185 samples (55 controls, 35 bipolar disorder, 44 schizophrenia, 51 major depression) were included in the analysis after removing 15 outliers. A total of 21,228 genes and 85,295 transcripts were included in the analysis. DESeq2 along with lfcShrink option was used for differential expression analysis between each diagnostic group versus the controls. The p-values were corrected using FDRtool 6 software in R.
Analysis of variance (ANOVA) analysis: DE genes (p<0.05) in each of the disorder were validated by ANOVA after correcting for the covariates. Dunnet's multiple comparisons tests were used as follow up tests to ANOVA.
DAVID Functional annotation:
Functional annotation was performed in DAVID which is a database of annotation, visualization and integrated discovery 7 (https://david.ncifcrf.gov/content.jsp?file=citation.htm). All 85,295 transcripts that met criteria for inclusion in the DE analysis were used as background genes.
Genotype data and Imputation: Samples were genotyped on Illumina HumanHap650Y, Omni1-quad, Omni5v1.0 and Omni5v1.1 arrays (Illumina Inc, San Diego, CA, USA). Markers that have minor allele frequency (MAF) <1%, genotype missing rate >5% and Hardy-Weingberg Equilibrium (HWE) p<10 -4 were excluded. All individuals had >95% genotype rate (--mind 0.05). Common markers across the multiple arrays were extracted and files were merged using PLINK2.0 (https://www.cog-genomics.org/plink/2.0/). All the samples were imputed against the Haplotype Reference Consortium (HRC release 1.1 panel) and pre-phasing was done using EAGLE2
on Sanger imputation server 8 (https://imputation.sanger.ac.uk). After imputation any markers with R 2 < 50%, MAF < 5%, and multi-allelic variants were excluded. All the markers were converted from hg19 to GRCh38 positions.
Expression quantitative trait loci (eQTL) analysis: Matrix eQTL software 9 was used to identify the eQTLs that affect the gene/transcript expression (http://www.bios.unc.edu/research/genomic_software/Matrix_eQTL/). complexity of the MHC region on chr6 (26MB-34MB), this region was excluded in the SMR analysis. All default parameters were used.
Enrichment analysis: For Schizophrenia, GWAS summary results, including index and credible SNPs, were downloaded from the PGC website (https://www.med.unc.edu/pgc/results-and-downloads). For Bipolar disorder and Major depression we took GWAS hits (SNPs with trait association p-values<10 -6 ) from the public summary statistics noted above and used PLINK 16 (http://zzz.bwh.harvard.edu/plink/) to extract all SNPs in linkage disequilibrium (r 2 >0.6) with the GWAS hits ("LD friends"). We also used PLINK to calculate linkage disequilibrium values among the index SNPs, LD friends, and sQTLs (p<0.05). We then extracted sQTL-GWAS SNP pairs with r 2 >0.6. The pairs were then pruned to get independent loci using the "indep-pairwise" option in PLINK (--indep-pairwise 50 5 0.5). The 1000Genomes European data 17 was used as reference (http://www.internationalgenome.org/data).
Heritability estimates:
Heritability estimates were performed with LDSC software 18 (https://github.com/bulik/ldsc), using the GWAS summary statistics for each disorder. To perform the partitioned heritability analysis for sQTLs and eQTLs we created a custom annotation file according to the instructions given in LDSC software (https://github.com/bulik/ldsc/wiki/LD-Score-Estimation-Tutorial), designating each SNP as an sQTL or an eQTL that was not also an sQTL. This annotation file was then used to partition the heritability between sQTLs and eQTLs in each disorder.
qPCR validation
Some genes and transcripts with expression that was high enough to produce reliable results by qPCR (baseMean > 500) and that were identified as DE in the DESeq2 analysis of the RNA-seq data were selected for validation.
At the gene-level, we selected DUSP1 and NR4A2, both of which were DE in BD, and HIGD2A, which was DE in BD and MDD. At the transcript level, we selected transcripts of ARID5B (ENST00000279873), NT5DC3
(ENST00000392876) and SF3A1 (ENST00000215793) that were DE in SCZ. Taqman probes were ordered from
